[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355659-105":59,"doc-detail-355659-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanotechnology-meets-immunotherapy-crosstalks-against-cancer","Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer","","The convergence of nanotechnology and immunotherapy is reshaping cancer treatment by addressing pharmacokinetic constraints and immune evasion seen in conventional therapies. Immunotherapy modalities, including checkpoint inhibition, adoptive cell transfer, and cancer vaccines, are limited by the immunosuppressive tumor microenvironment, off-target toxicity, and inadequate biodistribution. Engineered nanoparticles enable precise delivery of immunomodulators, antigens, and genetic payloads, while reprogramming the microenvironment to convert “cold” tumors into immunogenic “hot” phenotypes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanotechnology-meets-immunotherapy-crosstalks-against-cancer/355659/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanotechnology-meets-immunotherapy-crosstalks-against-cancer/355659.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do nanoparticles improve cancer immunotherapy compared with conventional therapies?","Question",{"text":112,"@type":113},"Engineered nanoparticles support more precise delivery of immunomodulators, antigens, and genetic payloads, enhance targeting, and reprogram the tumor microenvironment to promote immune activation while reducing systemic toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What key barriers limit immunotherapy efficacy in solid tumors?",{"text":117,"@type":113},"The immunosuppressive tumor microenvironment restricts immune cell infiltration and activation, contributing to immune evasion. Off-target toxicity and poor biodistribution of therapeutic agents also constrain effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"What strategies does the review highlight for nanoparticle design and therapeutic combinations?",{"text":121,"@type":113},"It emphasizes size-, charge-, and ligand-dependent approaches for lymph node targeting, APC activation, and sustained cargo release. It also discusses combinatorial co-delivery approaches, including checkpoint inhibitors with chemotherapeutics, to boost cytotoxic T-cell responses and mitigate systemic toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355659,1790176659,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Immunity, Inflammation and Disease   \nREVIEW ARTICLE   \nNanotechnology Meets Immunotherapy: Crosstalks Against Cancer  \nNima Javanmehr1 | Asal Moazzami Ashtyani2 | Robabehbeygom Ghafelehbashi3 | Fateme Mousavi4 | Hossein Teimouri5   \n1Student Research Committee, Babol University of Medical Sciences, Babol, Iran | 2Department of Medical Laboratory Sciences, Faculty of Allied Medicine, Bam University of Medical Sciences, Bam, Kerman, Iran | 3Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran | 4Shahid Rajaei Hospital, Qazvin University of Medical Sciences, Qazvin, Iran | 5Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran  \nCorrespondence: Hossein Teimouri ([Hosseinteimouri94@gmail.com](Hosseinteimouri94@gmail.com))  \nReceived: 23 June 2025 | Revised: 13 March 2026 | Accepted: 3 April 2026  \nKeywords: cancer immunotherapy | combination therapy | nanoparticles | nanotechnology | tumor microenvironment | tumor microenvironment  \nABSTRACT  \nBackground: The convergence of nanotechnology and immunotherapy has ushered in a transformative era in cancer treatment, offering new strategies to overcome pharmacokinetic limitations and immune evasion associated with conventional therapies. While immunotherapy, spanning checkpoint inhibitors, adoptive cell transfer, and cancer vaccines, has revolutionized oncology, its efficacy remains constrained by the immunosuppressive tumor microenvironment (TME), off‐target toxicity, and poor biodistribution of therapeutic agents.  \nObjective: This review elucidates how engineered nanoparticles (NPs) are redefining immune‐oncology by enabling the precise delivery of immunomodulators, antigens, and genetic payloads to target cells, while reprogramming the TME to convert “cold”tumors into immunogenic “hot” landscapes.  \nMethods: A literature search was conducted using PubMed, Scopus, and Google Scholar. The review was performed in a narrative and non‐systematic manner, focusing on studies addressing nanotechnology‐enhanced cancer immunotherapy. Results: We dissect the physicochemical and functional versatility of NPs, emphasizing size‐, charge‐, and ligand‐dependent strategies to enhance lymph node targeting, APC activation, and sustained cargo release. Innovations in metallic, lipid‐based, and biomimetic NPs are highlighted, including gold and lipid‐based NPs for enhanced immune responses. Furthermore, we explore combinatorial approaches, such as NP‐mediated co‐delivery of checkpoint inhibitors and chemotherapeutics, which amplify cytotoxic T‐cell responses and mitigate systemic toxicity. Clinical advancements, including Nab‐Paclitaxel and mRNA‐ loaded lipid NPs, underscore the translational potential of these platforms, with trials demonstrating improved survival and manageable adverse profiles.  \nConclusion: However, challenges persist in optimizing targeting precision, scalability, and long‐term safety. Integrating breakthroughs in material science, immunology, and bioengineering, this review charts a roadmap for next‐generation nano‐ immunotherapies, advocating patient‐specific designs and multimodal regimens. As the field strides toward clinical maturity, nanotechnology is poised to unlock the full potential of immunotherapy, paving the way for adaptive, immune‐guided, and potentially curative cancer therapies.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s) . Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.  \nImmunity, Inflammation and Disease, 2026; 14:e70437 1 of 17  \n[https://doi.org/10.1002/iid3.70437](https://doi.org/10.1002/iid3.70437)  \n1 | Introduction  \nConventional cancer therapies, for example, surgery, radiotherapy, and chemotherapy, face limitations such as severe side ","cbCaic4w3ptTRYBr","https://ap.wps.com/l/cbCaic4w3ptTRYBr","pdf",1255831,17,"English","# Introduction\n## Conventional cancer therapies and immunotherapy limitations\n## Role of nanomedicine and engineered nanoparticles\n# Methods\n# Results\n# Conclusion","[{\"question\":\"How do nanoparticles improve cancer immunotherapy compared with conventional therapies?\",\"answer\":\"Engineered nanoparticles support more precise delivery of immunomodulators, antigens, and genetic payloads, enhance targeting, and reprogram the tumor microenvironment to promote immune activation while reducing systemic toxicity.\"},{\"question\":\"What key barriers limit immunotherapy efficacy in solid tumors?\",\"answer\":\"The immunosuppressive tumor microenvironment restricts immune cell infiltration and activation, contributing to immune evasion. Off-target toxicity and poor biodistribution of therapeutic agents also constrain effectiveness.\"},{\"question\":\"What strategies does the review highlight for nanoparticle design and therapeutic combinations?\",\"answer\":\"It emphasizes size-, charge-, and ligand-dependent approaches for lymph node targeting, APC activation, and sustained cargo release. It also discusses combinatorial co-delivery approaches, including checkpoint inhibitors with chemotherapeutics, to boost cytotoxic T-cell responses and mitigate systemic toxicity.\"}]","Nanotechnology Meets Immunotherapy: Crosstalks Against Cancer | PDF",1790120388,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57c61e3c613853442242e4ac65d983ac.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0902e88f33de2afa72a70c20742b4e5.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46e1ee7bd2aed9778780e274177ca74c.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8601c6807d627d2924b0018efe233d1.webp",980,1287]